TITLE

Sangstat Will Continue to Offer Cyclosporine Therapy

PUB. DATE
September 1999
SOURCE
Worldwide Biotech;Sep99, Vol. 11 Issue 9, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the continued offering of a lower cyclosporine therapy of SangStat, The Transplant Company in Fremont, California, in response to Novartis filing a patent infringement lawsuit against SangStat in the United Kingdom. Claims that Novartis has violated the antitrust laws; United States Patent and Trademark Office issuance of two separate patents; Information on SangCya oral solution; Details on Sangstat.
ACCESSION #
2219616

 

Related Articles

  • India drugs giant rejects Novartis patent charges.  // Eastern Eye;4/11/2014, Issue 1246, p21 

    The article reports that Indian pharmaceutical firm Biocon has rejected the allegations imposed by Swiss pharmaceutical firm Novartis AG, which deals with the patent infringement of diabetes drug Galvus.

  • Broad claim construction leads to invalidity of Novartis's patent for EXELON Alzheimer's patch. Moore, Sebastian; Pead, Grace // Journal of Intellectual Property Law & Practice;Sep2015, Vol. 10 Issue 9, p653 

    The article discusses the court case Novartis AG & Others versus Focus Pharmaceuticals Ltd. & Others wherein the Patents Court of England and Wales ruled on April 27, 2015 that the patent of Novartis covering its EXELON rivastigmine transdermal patch to treat Alzheimer's disease is invalid.

  • ATG PREFERABLE TO OKT3 TO TREAT ACUTE REJECTION.  // Worldwide Biotech;Apr2001, Vol. 13 Issue 4, p3 

    Deals with the recommendation of SangStat company on the use of anti-thymocyte globulin on OKT3 for the treatment of acute rejection episodes.

  • FDA CLEARS SANGSTAT'S TWO HYMOGLOBULIN IND APPLICATIONS.  // Biotech Business;Sep2003, Vol. 16 Issue 9, p5 

    Reports the clearance of two investigational new drug applications of SangStat Medical Corp. by the U.S. Food and Drug Administration in September 2003.

  • Novartis Pulls Out of India. S. H. // Pharmaceutical Executive;Oct2007, Vol. 27 Issue 10, p26 

    The article reports that Novartis AG has pulled out its investment plans for the Gleevec drug from India to China due to refusal of authorities. The company claimed that the Indian's patent laws do not fulfill World Trade Organization requirements. Novartis was challenging the country to grant a...

  • Bayer wins Novartis pesticide suit. SCOTT, ALEX // Chemical Week;1/6/1999, Vol. 161 Issue 1, p45 

    Reports that Bayer company has won the suit brought by Novartis company regarding Bayer's patent on thiamethoxam insecticides. Rulings of the European Patent Office (EPO); Argument of Novartis on Bayer's patent on thiamethoxams.

  • Patent Watch. Harrison, Charlotte // Nature Reviews Drug Discovery;Mar2011, Vol. 10 Issue 3, p168 

    The article offers drug patent news briefs in the U.S. The Senate Committee on the Judiciary has passed the bill that aims to bring substantial changes to patent law on February 3, 2011. Kyoto University in Japan and the U.S.-based iPierian Inc. agreed to avert a potential dispute surrounding...

  • Active Pharmaceutical Ingredient Watch.  // Chemical Market Reporter;4/8/2002, Vol. 261 Issue 14, p11 

    Presents news briefs on the pharmaceutical industry as of April 8, 2002. Details on a patent infringement suit filed by Aventis Pharmaceuticals Inc. against Impax Laboratories Inc.; Notification received by Sanofi-Synthelabo Inc.; Approval received by Sicor Inc. for a generic version of...

  • SangStat sells shares, gains $10.2 million.  // Modern Healthcare;1/3/94, Vol. 24 Issue 1, p52 

    Reports on SangStat Medical Corp.'s initial public offering of shares of common stock. Amount raised; Number of shares sold; Company products; Underwriters.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics